Evaluating S100B as a serum biomarker for central neurosarcoidosis - 05/02/20
, D.C. Patel b, 1, J.O. Tavee c, D.A. Culver dAbstract |
Background |
S100B is a calcium-binding protein found primarily in glial cells. In the setting of neuronal injury and disruption of the blood brain barrier, S100B can leak into the cerebrospinal fluid and systemic circulation.
Objectives |
To determine if serum S100B distinguishes patients with central neurosarcoidosis (NS) from patients with extra-neurologic sarcoidosis (ENS) and healthy controls, and if S100B levels correlate with MRI measures of disease burden.
Methods |
Patients were enrolled from the Cleveland Clinic Sarcoidosis Center. Patients with traumatic brain injury, central nervous system (CNS) infections, CNS malignancy, neurodegenerative disorders, schizophrenia, bipolar disorder, or melanoma were excluded. S100B levels were compared between patients with NS, ENS, and healthy controls, and between NS patients with varying degrees of post-contrast enhancement on MRI.
Results |
Median (interquartile range) S100B levels were 101 pg/mL (92, 136) for 11 NS patients, 89 pg/mL (73, 107) for 11 ENS patients, and 60 pg/mL (39, 74) for 26 healthy controls. There was a significant difference between NS and control groups (p = 0.01). The difference between NS and ENS groups did not rise to the level of statistical significance (p = 0.178). S100B levels were significantly different between NS patients with varying degrees of enhancement on MRI (p = 0.04).
Conclusions |
S100B deserves additional study as a biomarker for CNS injury in NS. It may be useful as a longitudinal measure of disease activity.
Le texte complet de cet article est disponible en PDF.Highlights |
• | S100B levels are higher in neurosarcoidosis patients compared to healthy controls. |
• | Differences between S100B levels in neurosarcoidosis and sarcoidosis patients are not statistically significant. |
• | S100B levels are higher in neurosarcoidosis patients with greater disease burden on MRI. |
Keywords : S100B, Biomarker, Sarcoidosis, Neurosarcoidosis
Plan
Vol 162
Article 105855- février 2020 Retour au numéro
Article précédent
- Time-to-death in chronic respiratory failure on home mechanical ventilation: A cohort study
- Esther I. Schwarz, Mike Mackie, Nick Weston, Laura Tincknell, Gurpreet Beghal, Michael C.F. Cheng, Michelle Ramsay, Eui-Sik Suh, Georgios Kaltsakas, Hina Pattani, Philip Marino, Patrick B. Murphy, Nicholas Hart, Joerg Steier
- A randomized controlled trial of respiratory physiotherapy in lower respiratory tract infections
- Alda Marques, Cátia Pinho, Silvia De Francesco, Paula Martins, Joana Neves, Ana Oliveira
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?